Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinengotinib + Toripalimab in Advanced Urological Tumors
NCT06221774Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Feb 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tinengotinib in clear cell renal cell carcinoma (ccRCC), urothelial carcinoma (UC) and metastatic castration-resistant prostate cancer (mCRPC) (5 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 12 weeks, Objective Response Rate at 1 year and 1 more. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
tinengotinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)urothelial carcinoma (UC)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06221774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221774.